GoAI
Get started
Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

GOSS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.1547

−$0.0028 · -1.78%

Aug 21, 4:00 PM ET

GOSS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

63

Undervalued

Momentum

21

Weakening

Sentiment

41

Mixed

Risk resilience

22

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Faheem Hasnain
Listed since
Feb 8, 2019
Employees
162

Market position

Day range

Current $0.1547

52-week range

Current $0.1547

Open
$0.1685
Previous close
$0.1575
Volume
131.36M
6.12× average
Average volume
21.46M
Average daily volume
Market cap
75.62M USD
Beta
2.01
Market reference 1
50-day average
$0.1675
-7.62% below average
200-day average
$1.2245
-87.37% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
873.58M USD
P/E (TTM)
-0.27×
P/B (TTM)
-0.53×
P/S (TTM)
1.42×
EV / EBITDA
-5.51×
Earnings yield
-24.05%
Free cash flow yield
-24.19%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.56%
Operating margin
-311.70%
Net margin
-235.00%
Return on equity
138.78%
Return on assets
-98.91%
Return on invested capital
-148.67%

Financial health

Debt / equity
-0.42×
Current ratio
2.64×
Altman Z-score
-35.64
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends145%-35%-216%-397%Gross margin, FY2024: 100.00%Gross margin, FY2025: 97.93%Operating margin, FY2024: -52.24%Operating margin, FY2025: -336.81%Net margin, FY2024: -49.28%Net margin, FY2025: -351.49%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 97.93%. Operating margin FY2024 -52.24%. Operating margin FY2025 -336.81%. Net margin FY2024 -49.28%. Net margin FY2025 -351.49%.

Income trends

Revenue

48.47M USD-57.74%

Operating income

−163.25M USD-172.46%

Net income

−170.37M USD-201.39%
Income trends across reported periods149.57M USD10.09M USD−129.39M USD−268.87M USDRevenue, FY2024: 114.7M USDRevenue, FY2025: 48.47M USDOperating income, FY2021: −216.12M USDOperating income, FY2022: −218.59M USDOperating income, FY2023: −183.76M USDOperating income, FY2024: −59.92M USDOperating income, FY2025: −163.25M USDNet income, FY2021: −234M USDNet income, FY2022: −229.38M USDNet income, FY2023: −179.82M USDNet income, FY2024: −56.53M USDNet income, FY2025: −170.37M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 114.7M USD. Revenue FY2025 48.47M USD. Operating income FY2021 −216.12M USD. Operating income FY2022 −218.59M USD. Operating income FY2023 −183.76M USD. Operating income FY2024 −59.92M USD. Operating income FY2025 −163.25M USD. Net income FY2021 −234M USD. Net income FY2022 −229.38M USD. Net income FY2023 −179.82M USD. Net income FY2024 −56.53M USD. Net income FY2025 −170.37M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue48.47M USD114.7M USD———
Cost of goods sold1M USD————
Gross profit47.47M USD114.7M USD———
Research and development174.09M USD138.49M USD135.3M USD170.92M USD170.27M USD
Selling, general, and administrative37.63M USD36.13M USD38.46M USD47.61M USD45.78M USD
Operating expenses210.72M USD174.62M USD183.76M USD218.59M USD216.12M USD
Interest income1.97M USD1.78M USD2M USD1.58M USD761K USD
Interest expense10.99M USD11.52M USD13.51M USD13.88M USD19.44M USD
Depreciation and amortization1M USD4.15M USD4.39M USD4.43M USD5.17M USD
Operating income−163.25M USD−59.92M USD−183.76M USD−218.59M USD−216.12M USD
Net income−170.37M USD−56.53M USD−179.82M USD−229.38M USD−234M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 5 misses, 1 met estimate
Average EPS surprise
+3.94%
11 comparable reports
Latest EPS result
-0.08
Estimate -0.12 · Beat by 35.19%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.06-0.12-0.19-0.25Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual -0.15, estimate -0.17, surprise +11.76%, Beat. Q2 2025, reported May 15, 2025: actual -0.16, estimate -0.18, surprise +11.11%, Beat. Q3 2025, reported Aug 5, 2025: actual -0.17, estimate -0.18, surprise +5.56%, Beat. Q4 2025, reported Nov 5, 2025: actual -0.21, estimate -0.19, surprise -10.53%, Miss. Q1 2026, reported Mar 17, 2026: actual -0.21, estimate -0.2, surprise -5.00%, Miss. Q2 2026, reported May 18, 2026: actual -0.2, estimate -0.17, surprise -17.65%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.08, estimate -0.123, surprise +35.19%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.07, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates18.02M13.04M8.06M3.08MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual 9.38M USD, estimate 6.83M USD, surprise +37.24%, Beat. Q2 2025, reported May 15, 2025: actual 9.89M USD, estimate 3.95M USD, surprise +150.53%, Beat. Q3 2025, reported Aug 5, 2025: actual 11.49M USD, estimate 5.41M USD, surprise +112.41%, Beat. Q4 2025, reported Nov 5, 2025: actual 13.29M USD, estimate 7.53M USD, surprise +76.64%, Beat. Q1 2026, reported Mar 17, 2026: actual 13.8M USD, estimate 7.52M USD, surprise +83.44%, Beat. Q2 2026, reported May 18, 2026: actual 16.96M USD, estimate 4.67M USD, surprise +263.19%, Beat. Q3 2026, reported Aug 13, 2026: actual 9.24M USD, estimate 3.63M USD, surprise +154.57%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 10.79M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$0.65

320.17% upside
Past 12 months12-month forecastHigh $1.00Average $0.65Low $0.30

Rating distribution

17 ratings
Strong buy00%
Buy1059%
Hold529%
Sell212%
Strong sell00%

GOSS news

gurufocus.com

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercializa

Read source
businesswire.com

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the…

Read source
zacks.com

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago.

Read source
businesswire.com

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the…

Read source
prnewswire.com

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Gossamer Bio, Inc. (NASDAQ: GOSS) breached their fiduciary duties to…

Read source
benzinga.com

Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate

Gossamer Bio Inc. (NASDAQ:GOSS) stock is trading higher on Monday as the company is preparing to submit a New Drug Application (NDA) for its lead candidate, seralutinib, in September 2026 following a pre-NDA Type B…

Read source

GOSS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding GOSS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.17M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
526.51K
Weight
0.00%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
380.24K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
154.96K
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
93.05K
Weight
0.00%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
Invesco RAFI US 1500 Small-Mid ETF logoInvesco RAFI US 1500 Small-Mid ETFPRFZ
Market value
87.43K
Weight
0.00%
AUM
2.87B USD
Expense ratio
0.34%
Price / 1D
$55.89+0.87%
Eventide Small Cap ETF logoEventide Small Cap ETFESSC
Market value
35.51K
Weight
0.10%
AUM
36M USD
Expense ratio
0.49%
Price / 1D
$30.87+0.46%
Invesco Nasdaq Biotechnology ETF logoInvesco Nasdaq Biotechnology ETFIBBQ
Market value
2.15K
Weight
0.00%
AUM
94.57M USD
Expense ratio
0.19%
Price / 1D
$36.29+1.37%

Continue in GoAI

Research GOSS

research.disclaimer